GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Intersect ENT Inc (NAS:XENT) » Definitions » EBITDA Margin %

Intersect ENT (Intersect ENT) EBITDA Margin % : -122.12% (As of Mar. 2022)


View and export this data going back to 2014. Start your Free Trial

What is Intersect ENT EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Intersect ENT's EBITDA for the three months ended in Mar. 2022 was $-26.3 Mil. Intersect ENT's Revenue for the three months ended in Mar. 2022 was $21.6 Mil. Therefore, Intersect ENT's EBITDA margin for the quarter that ended in Mar. 2022 was -122.12%.


Intersect ENT EBITDA Margin % Historical Data

The historical data trend for Intersect ENT's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intersect ENT EBITDA Margin % Chart

Intersect ENT Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -16.76 -19.39 -36.95 -83.35 -140.59

Intersect ENT Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -73.48 -52.85 -120.22 -288.26 -122.12

Competitive Comparison of Intersect ENT's EBITDA Margin %

For the Medical Devices subindustry, Intersect ENT's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intersect ENT's EBITDA Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Intersect ENT's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Intersect ENT's EBITDA Margin % falls into.



Intersect ENT EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Intersect ENT's EBITDA Margin % for the fiscal year that ended in Dec. 2021 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2021 )/Revenue (A: Dec. 2021 )
=-150.076/106.748
=-140.59 %

Intersect ENT's EBITDA Margin % for the quarter that ended in Mar. 2022 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2022 )/Revenue (Q: Mar. 2022 )
=-26.347/21.575
=-122.12 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Intersect ENT  (NAS:XENT) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Intersect ENT EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Intersect ENT's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Intersect ENT (Intersect ENT) Business Description

Traded in Other Exchanges
N/A
Address
1555 Adams Drive, Menlo Park, CA, USA, 94025
Intersect ENT Inc are a commercial drug delivery company committed to improving the quality of life for patients with ear, nose and throat conditions. It offer's PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis and PROPEL contour, a steroid-releasing implant to frontal and maxillary sinus ostia or openings of the dependent sinuses. The company generates revenues from the sale of our PROPEL family of products.
Executives
Elisabeth Sandoval director C/O KYTHERA BIOPHARMACEUTICALS, INC., 30930 RUSSELL RANCH ROAD, 3RD FLOOR, WESTLAKE VILLAGE CA 91362
Neil A Hattangadi director 1555 ADAMS DRIVE MENLO PARK CA 94025
Reyna M Fernandez officer: Chief Human Resource Officer C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Patrick A Broderick officer: EVP, GC & Corporate Secretary C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Thomas A. West director, officer: President and CEO C/O INTERSECT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Richard A Meier officer: EVP & Chief Financial Officer C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Binney Robert H Jr officer: Vice President, Sales 1555 ADAMS DRIVE C/O INTERSECT ENT, INC. MENLO PARK CA 94025
Susan P Stimson officer: Vice President, Marketing 1555 ADAMS DRIVE C/O INTERSECT ENT, INC. MENLO PARK CA 94025
Lisa D Earnhardt director, officer: See Remarks 1555 ADAMS DRIVE, C/O INTERSECT ENT, INC., MENLO PARK CA 94025
David Aaron Lehman officer: General Counsel C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Jeryl L Hilleman officer: Chief Financial Officer C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Christine R Kowalski officer: Chief Operations Officer C/O INTERSECT ENT, INC. 1555 ADAMS DRIVE MENLO PARK CA 94025
Mead Dana G Jr. director 2750 SAND HILL ROAD, MENLO PARK CA 94025
Richard E Kaufman officer: See Remarks 1555 ADAMS DRIVE C/O INTERSECT ENT, INC. MENLO PARK CA 94025
Gwen R. Carscadden officer: Chief People Officer C/O INTERSECT ENT, INC. 1555 ADAMS DRIVE MENLO PARK CA 94025

Intersect ENT (Intersect ENT) Headlines

From GuruFocus

Intersect ENT to Participate in Upcoming Investor Conferences

By Business Wire Business Wire 02-02-2021

Intersect ENT Announces New Appointments to Executive Leadership Team

By Business Wire Business Wire 11-18-2020

Intersect ENT Announces Appointment of New Vice President of Sales

By Business Wire Business Wire 05-04-2021